CDTP 003
Alternative Names: CDTP-003Latest Information Update: 04 Sep 2024
At a glance
- Originator Chronos Therapeutics
- Developer TheraCryf
- Class
- Mechanism of Action Tropomyosin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Post-traumatic stress disorders
Most Recent Events
- 14 Sep 2023 Early research in Post-traumatic stress disorders in United Kingdom (unspecified route) (Chronos Therapeutics pipeline, September 2023)